Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine Maintenance in Adult ADHD (LYDO)
NCT00700427Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2008
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Jun 2008; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00700427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00700427.